The detection of metastases in Merkel cell carcinoma (MCC) requires additional testing, such as pancytokeratin (panCK) or CK20, with no guarantee of success. Recent findings have identified transcription factor SOX11 and insulinoma-associated protein 1 (INSM1) as sensitive nuclear neuroendocrine markers, but their usefulness in MCC has not been proven.

In recently published work from Air Force Medical University, analysis of tumor tissues isolated from different patient-derived xenografts revealed significantly increased expression of FXYD5 in the metastatic tumors compared to the primary tumors, and analysis of patient database confirmed significantly elevated expression of FXYD5 in gastric cancer tissues compared to normal gastric tissues.

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists.

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the nonmetastatic lung microenvironment of several cancer types, the development of a prothrombosis niche promotes metastasis formation through the release of small extracellular vesicles loaded with an integrin protein.

The abscopal effect occurs when therapy leads to the regression of metastases distant from the target tumor. In the current study, researchers from INSERM aimed to evaluate the abscopal effect potentially inducted by the use the targeted radionuclide therapy (TRT) candidate, [131I]ICF-01012, which has been previously shown to target only pigmented metastases.

Breast cancer cells, when disseminated to other secondary organs such as the lungs, may stay in a dormant state for years, even decades. But the mechanisms that limit their expansion are not well understood. This is what researchers call a dormant mesenchymal-like phenotype before metastasis to the lungs. Now, scientists have shown in a study published Oct. 7, 2024, in Cell, that the limiting of disseminated breast cancer cells (DCCs) to metastasize in the lungs is due to alveolar macrophages, which activate signals that make DCCs stay dormant.

Breast cancer cells, when disseminated to other secondary organs such as the lungs, may stay in a dormant state for years, even decades. But the mechanisms that limit their expansion are not well understood. This is what researchers call a dormant mesenchymal-like phenotype (M-like) before metastasis to the lungs. Now, scientists have shown in a study published Oct. 7, 2024, in Cell, that the limiting of disseminated breast cancer cells (DCCs) to metastasize in the lungs is due to alveolar macrophages (AMs), which activate signals that make DCCs stay dormant.

Mink Therapeutics Inc. and Autonomous Therapeutics Inc. have announced a research collaboration aimed at targeting and treating metastatic tumors.